[Relapses in children with nephroblastoma--a single centre experience].
The aim of the study was to assess the incidence of relapse and outcome of treatment in children with nephroblastoma relapse.


METHODS
In the years 1989-2002 at our centre 67 children were treated for nephroblastoma. Patients were divided into two subgroups. Group I comprised 25 children treated in accordance with the SIOP-9 programme, whilst group II consisted of 42 patients following the SIOP 93-01 protocol.


RESULTS
In group I, five children had relapse diagnosed: local in 2, pulmonary in 2 and cerebral in one case. Two of the cases were diagnosed during the treatment, and the other 3 after 1 to 19 months from the completion of treatment. In group II relapse was diagnosed in 4 children: local in 2 and pulmonary in 2 cases. One case was diagnosed while on treatment, and the other 3 were diagnosed 1,2 and 4 months after completion of treatment. Among the children who followed the SIOP-9 programme three patients died, while among those following SIOP 93-01 two patients died.


CONCLUSIONS
The prognosis in patients who relapsed remains uncertain. The histological type of tumour and the moment of relapse occurrence are significant prognostic factors.
Stefanowicz
Joanna
J
Klinika Pediatrii, Hematologii, Onkologii i Endokrynologii Akademii Medycznej w Gdańsku.
Sierota
Danuta
D
Połczyńska
Katarzyna
K
Adamkiewicz-Drozyńska
Elzbieta
E
Szołkiewicz
Anna
A
Bień
Ewa
E
Stachowicz-Stencel
Teresa
T
Komasara
Leszek
L
Czauderna
Piotr
P
Balcerska
Anna
A
D000971:Antineoplastic Combined Chemotherapy Protocols; D002648:Child; D003609:Dactinomycin; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011044:Poland; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome; D014750:Vincristine; D009396:Wilms Tumor / Q000188:drug therapy*
D003609:Dactinomycin; D014750:Vincristine